Literature DB >> 30105813

MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Jianan Chen1,2, Yan Yu1,2, Xiaolong Chen1,2, Yuting He1,2, Qiuyue Hu1,2, Hongqiang Li2, Qicai Han2, Fang Ren2, Juan Li1,2, Chao Li3, Jie Bao2, Zhigang Ren1,2, Zhenfeng Duan4, Guangying Cui1,2, Ranran Sun1,2.   

Abstract

OBJECTIVES: Gallbladder carcinoma (GBC) is the most highly aggressive cancer of biliary tract, but effective therapeutics are lacking. Emerging evidence has unveiled that miR-139-5p is aberrantly downregulated in cancers, including GBC. However, the functions and mechanisms of miR-139-5p in GBC remain unclear.
MATERIALS AND METHODS: MiR-139-5p-overexpression was established in GBC cell lines, after which cell proliferation, migration, invasion, colony formation, and glucose metabolism were assayed in vitro. Subsequently, bioinformatics prediction and dual-luciferase reporter were performed to confirm that pyruvate kinase M2 (PKM2) was a direct target of miRNA-139-5p. Xenograft mouse models were applied to investigate the role of miR-139-5p in GBC tumourigenicity in vivo. In situ hybridization and immunohistochemical assays were performed to determine the relationships among miR-139-5p, PKM2 expression and clinical malignancies in GBC samples.
RESULTS: We found that miR-139-5p was substantially downregulated in GBC tissues. Low expression of miR-139-5p was significantly associated with poor clinical outcomes. GBC cell proliferation, migration, and invasion could be inhibited by overexpression of miR-139-5p either in vitro or in vivo. In addition, miR-139-5p overexpression could directly inhibit PKM2 expression and lead to suppression of glucose consumption, lactate production, and cellular ATP levels. Moreover, PKM2 was frequently upregulated in GBC and correlated with poor prognosis. Mechanistically, miRNA-139-5p inhibited cell proliferation, migration, and glycolysis in GBC, at least in part, by repressing PKM2.
CONCLUSIONS: These results demonstrated a novel role for miR-139-5p/PKM2 in GBC progression and provided potential prognostic predictors for GBC patients.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30105813      PMCID: PMC6528956          DOI: 10.1111/cpr.12510

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  46 in total

Review 1.  Emerging roles of PKM2 in cell metabolism and cancer progression.

Authors:  Weibo Luo; Gregg L Semenza
Journal:  Trends Endocrinol Metab       Date:  2012-07-21       Impact factor: 12.015

2.  MicroRNA-139-3p indicates a poor prognosis of colon cancer.

Authors:  Xiaojing Liu; Bensong Duan; Yuanyuan Dong; Chengzhi He; Hongmei Zhou; Haihui Sheng; Hengjun Gao; Xizhi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.

Authors:  Gongcai Qiu; Yujia Lin; Haogang Zhang; Dequan Wu
Journal:  Biochem Biophys Res Commun       Date:  2015-05-27       Impact factor: 3.575

4.  The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2.

Authors:  Carmen Chak-Lui Wong; Chun-Ming Wong; Edmund Kwok-Kwun Tung; Sandy Leung-Kuen Au; Joyce Man-Fong Lee; Ronnie Tung-Ping Poon; Kwan Man; Irene Oi-Lin Ng
Journal:  Gastroenterology       Date:  2010-10-15       Impact factor: 22.682

5.  Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma.

Authors:  Y-P Lv; W Shi; H-X Liu; X-J Kong; D-L Dai
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-02       Impact factor: 3.507

6.  miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis.

Authors:  Lei Li; Baiwen Li; Dafan Chen; Liyan Liu; Chen Huang; Zhanjun Lu; Lungen Lun; Xinjian Wan
Journal:  Oncol Rep       Date:  2015-05-04       Impact factor: 3.906

7.  miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

Authors:  Liana Adam; Meng Zhong; Woonyoung Choi; Wei Qi; Milena Nicoloso; Ameeta Arora; George Calin; Hua Wang; Arlene Siefker-Radtke; David McConkey; Menashe Bar-Eli; Colin Dinney
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

8.  MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme.

Authors:  Shouping Dai; Xianjun Wang; Xiao Li; Yuandong Cao
Journal:  Biochem Biophys Res Commun       Date:  2015-10-09       Impact factor: 3.575

Review 9.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

10.  MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Authors:  Jianan Chen; Yan Yu; Xiaolong Chen; Yuting He; Qiuyue Hu; Hongqiang Li; Qicai Han; Fang Ren; Juan Li; Chao Li; Jie Bao; Zhigang Ren; Zhenfeng Duan; Guangying Cui; Ranran Sun
Journal:  Cell Prolif       Date:  2018-08-13       Impact factor: 6.831

View more
  41 in total

1.  Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Bin Yu; Youming Ding; Xiaofeng Liao; Changhua Wang; Bin Wang; Xiaoyan Chen
Journal:  Dig Dis Sci       Date:  2019-04-04       Impact factor: 3.199

2.  The long non-coding RNA MIAT/miR-139-5p/MMP2 axis regulates cell migration and invasion in non-small-cell lung cancer.

Authors:  Fanye Zeng; Ning Yu; Yanyan Han; Julaiti Ainiwaer
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

3.  High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition.

Authors:  Yulei Gu; Chao Li; Lili Xiao; Juan Li; Hui Pei; Dong Xu; Yumin Jiang; Xiaofan Zhang; Luanluan Zhang; Kongfei Li; Zhiqiang Zhu; Xiaolong Chen
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

4.  Long noncoding RNA CASC15 predicts unfavorable prognosis and exerts oncogenic functions in non-small cell lung cancer.

Authors:  Min Li; Yu Chen; Jicun Zhu; Zhan Gao; Tao Wang; Pengli Zhou
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

5.  UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer.

Authors:  Jianhua Yu; Lawrence Shi; Weiguo Lin; Baochun Lu; Yunfeng Zhao
Journal:  Biochem Pharmacol       Date:  2019-12-05       Impact factor: 5.858

Review 6.  The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.

Authors:  Dexter L Puckett; Mohammed Alquraishi; Winyoo Chowanadisai; Ahmed Bettaieb
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

7.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

8.  MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Authors:  Jianan Chen; Yan Yu; Xiaolong Chen; Yuting He; Qiuyue Hu; Hongqiang Li; Qicai Han; Fang Ren; Juan Li; Chao Li; Jie Bao; Zhigang Ren; Zhenfeng Duan; Guangying Cui; Ranran Sun
Journal:  Cell Prolif       Date:  2018-08-13       Impact factor: 6.831

9.  Long non-coding RNA TTN antisense RNA 1 facilitates hepatocellular carcinoma progression via regulating miR-139-5p/SPOCK1 axis.

Authors:  Xinghao Zhu; Shiqing Jiang; Zongyao Wu; Tonghua Liu; Wei Zhang; Lili Wu; Lijun Xu; Mingliang Shao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

10.  miR‑135a‑5p inhibits tumor invasion by targeting ANGPT2 in gallbladder cancer.

Authors:  Haiyan Diao; Xing Xu; Bin Zhao; Guanghua Yang
Journal:  Mol Med Rep       Date:  2021-05-26       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.